Vanderbilt-Ingram Cancer Center

See also:

• Thoracic/Head and Neck Cancer Research Program
• Medicine: Hematology/Oncology
• Pharmacology
• BRET: Biomedical Research Education & Training Faculty Listing
• PubMed Listing of Dr. Hande's Publications

Learn More About Kenneth R. Hande's Specialties:

• Adrenocortical Cancer
• Anal Cancer
• Bile Duct (Extrahepatic) Cancer
• Carcinoid Tumors
• Carcinoma of Unknown Primary
• Colon Cancer
• Esophageal Cancer
• Gallbladder Cancer
• Islet Cell Cancer (Pancreas)
• Liver Cancer
• Lung Cancer - Non Small Cell
• Lung Cancer - Small Cell
• Malignant Mesothelioma
• Pancreatic Cancer
• Rectal Cancer
• Small Intestine Cancer
• Soft Tissue Sarcoma
• Stomach (Gastric) Cancer
• Thymoma and Thymic Carcinoma

Dr. Hande is a medical oncologist who specializes in the treatment of carcinoma of the unknown primary site, phase I drug development, carcinoid tumors, lung cancer and sarcomas. His clinical research interests are in the pharmacology of drugs used in cancer therapy with a focus in the metabolism, elimination, toxicity and efficacy of antineoplastic agents.
Read more ....

Publications

• Lockhart, A Craig, Howard, Martin, Hande, Kenneth R, Roth, Bruce J, Berlin, Jordan D, Vreeland, Franzanne, Campbell, Angela, Fontana, Erminia, Fiorentini, Francesca, Fowst, Camilla, Paty, Victoria A, Lankford, Odessa, Rothenberg, Mace L A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res, 10(2), 468-75, 2004.
• Hande, Kenneth R, Collier, Mary, Paradiso, Linda, Stuart-Smith, Jill, Dixon, Mary, Clendeninn, Neil, Yeun, Geoff, Alberti, Donna, Binger, Kim, Wilding, George Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin Cancer Res, 10(3), 909-15, 2004.
• Clapp, JaNae M, Hande, Kenneth R Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 20125-49, 2002.
• Dowell, J E, Garrett, A M, Shyr, Y, Johnson, D H, Hande, K R A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer, 91(3), 592-7, 2001.
• Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H, , Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer, 34(3), 441-9, 2001.
• Toonen, T R, Hande, K R Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif, 19129-47, 2001.
• Choy, H, De Vore, R F, Hande, K R, Porter, L L, Rosenblatt, P A, Slovis, B, Laporte, K, Shyr, Y, Johnson, D H A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Clin Lung Cancer, 1 Suppl 1S27-31, 2000.
• Choy, H, Devore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, Johnson, D H A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys, 47(4), 931-7, 2000.
• Dang, T P, Gazdar, A F, Virmani, A K, Sepetavec, T, Hande, K R, Minna, J D, Roberts, J R, Carbone, D P Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst, 92(16), 1355-7, 2000.
• Nicholson, B P, Paul, D M, Hande, K R, Shyr, Y, Meshad, M, Cohen, A, Johnson, D H Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Clin Breast Cancer, 1(2), 136-43; discussion 144, 2000.
• Choy, H, Chakravarthy, A, Devore, R F, Jagasia, M, Hande, K R, Roberts, J R, Johnson, D H, Yunus, F Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology (Huntingt), 14(7 Suppl 5), 43-6, 2000.
• Rothenberg, M L, Nelson, A R, Hande, K R New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells, 17(4), 237-40, 1999.
• Hande, K R Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta, 1400(1-3), 173-84, 1998.
• Hande, K R Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer, 34(10), 1514-21, 1998.
• Rothenberg, , Nelson, , Hande, New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Oncologist, 3(4), 271-274, 1998.
• Johnson, D H, Paul, D, Hande, K R Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Semin Oncol, 24(1 Suppl 3), S22-5, 1997.
• Nicholson, B, Paul, D, Shyr, Y, Garrett, M, Hande, K R, Johnson, D H Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. Semin Oncol, 24(4 Suppl 11), S11-20-S11-23, 1997.
• Choy, H, DeVore, R F, Hande, K R, Porter, L L, Rosenblatt, P, Yunus, F, Schlabach, L, Smith, C, Shyr, Y, LaPorte, K, Johnson, D H Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol, 24(4 Suppl 12), S12-21-S12-26, 1997.
• Johnson, D H, Paul, D M, Hande, K R, Shyr, Y, Blanke, C, Murphy, B, Lewis, M, De Vore, R F Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol, 14(7), 2054-60, 1996.
• Johnson, D H, Paul, D M, Hande, K R, DeVore, R Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46). Semin Oncol, 23(6 Suppl 16), 42-6, 1996.
• Deegan, P M, Basinger, M A, Jones, M M, Hande, K R Prevention of cisplatin nephrotoxicity by exogenous atrial natriuretic peptide. Toxicology, 106(1-3), 159-66, 1996.
• Hande, The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist, 1(4), 234-239, 1996.
• Hande, K R The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells, 14(1), 18-24, 1996.
• Anthony, L B, Boeve, T J, Hande, K R Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol, 36(2), 125-8, 1995.
• Johnson, D H, Paul, D M, Hande, K R, DeVore, R F Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46. Semin Oncol, 22(4 Suppl 9), 30-3, 1995.
• Deegan, P M, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R Protection from cisplatin nephrotoxicity by A68828, an atrial natriuretic peptide. Ren Fail, 17(2), 117-23, 1995.
• Deegan, P M, Nolan, C, Ryan, M P, Basinger, M A, Jones, M M, Hande, K R The role of the renin-angiotensin system in cisplatin nephrotoxicity. Ren Fail, 17(6), 665-74, 1995.
• Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M, Greco, F A Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Cancer, 73(11), 2824-31, 1994.
• Hande, K R, Garrow, G C Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med, 94(2), 133-9, 1993.
• Hande, K R, Krozely, M G, Greco, F A, Hainsworth, J D, Johnson, D H Bioavailability of low-dose oral etoposide. J Clin Oncol, 11(2), 374-7, 1993.
• Thompson, D S, Hainsworth, J D, Hande, K R, Holzmer, M C, Greco, F A Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol, 11(7), 1322-8, 1993.
• Murphy, P B, Hainsworth, J D, Greco, F A, Hande, K R, DeVore, R F, Johnson, D H A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer, 69(2), 370-5, 1992.
• Hande, K R Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids. Curr Opin Oncol, 4(6), 1080-8, 1992.
• Ormond, P M, Basinger, M A, Jones, M M, Hande, K R Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. J Pharmacol Exp Ther, 262(1), 246-51, 1992.
• Johnson, D H, DeVore, R, Greco, F A, Walls, J, Thomas, M, Hande, K R, Hainsworth, J D Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Semin Oncol, 19(1 Suppl 2), 50-6, 1992.
• Johnson, D H, Hainsworth, J D, DeVore, R, Hande, K R, Greco, F A Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology, 49 Suppl 157-61; discussion 61-2, 1992.
• Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A Combination chemotherapy with oral etoposide. Semin Oncol, 19(6 Suppl 14), 19-24, 1992.
• Hande, K R Etoposide pharmacology. Semin Oncol, 19(6 Suppl 13), 3-9, 1992.
• Waits, T M, Johnson, D H, Hainsworth, J D, Hande, K R, Thomas, M, Greco, F A Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol, 10(2), 292-6, 1992.
• Greco, F A, Murphy, P B, Hainsworth, J D, Hande, K R, Johnson, D H Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology, 49 Suppl 134-8; discussion 39, 1992.
• Johnson, D H, Hainsworth, J D, Hande, K R, Greco, F A Current status of etoposide in the management of small cell lung cancer. Cancer, 67(1 Suppl), 231-44, 1991.
• Johnson, D H, Strupp, J, Greco, F A, Stewart, J, Merrill, W, Malcolm, A, Hande, K R, Hainsworth, J D Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer, 68(6), 1216-20, 1991.
• Hande, K R, Wolff, S N, Greco, F A, Hainsworth, J D, Reed, G, Johnson, D H Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol, 8(6), 1101-7, 1990.
• Hande, K R, Kuttesch, J, Hamilton, M, Satterlee, W, Jackson, L, Grindey, G, Hainsworth, J D Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res, 50(13), 3910-4, 1990.
• Johnson, D H, Greco, F A, Strupp, J, Hande, K R, Hainsworth, J D Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol, 8(10), 1613-7, 1990.
• Anthony, L B, Long, Q C, Struck, R F, Hande, K R The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol, 27(2), 125-30, 1990.
• Hainsworth, J D, Johnson, D H, Hande, K R, Greco, F A Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens. Am J Clin Oncol, 12(4), 345-9, 1989.
• Mangum, M D, Greco, F A, Hainsworth, J D, Hande, K R, Johnson, D H Combined small-cell and non-small-cell lung cancer. J Clin Oncol, 7(5), 607-12, 1989.
• Hainsworth, J D, Hande, K R, Satterlee, W G, Kuttesch, J, Johnson, D H, Grindey, G, Jackson, L E, Greco, F A Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res, 49(18), 5217-20, 1989.
• List, A F, Greer, J P, Cousar, J C, Stein, R S, Johnson, D H, Reynolds, V H, Greco, F A, Flexner, J M, Hande, K R Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol, 6(7), 1125-33, 1988.
• Johnson, D H, Porter, L L, List, A F, Hande, K R, Hainsworth, J D, Greco, F A Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am J Med, 81(6), 962-8, 1986.